ALPELISIB FOR PIK3CA-MUTATED, HR+ ADVANCED BREAST CANCER.
Numerous studies have evaluated the role of PI3K inhibitors in breast cancer, some with positive results but an excess toxicity profile. The SOLAR-1 trial is the first to show a clinically meaningful benefit (PFS nearly doubled) with the addition of alpelisib in patients who harbor a PIK3CA mutation. Although very few patients on this study […]
ALPELISIB FOR PIK3CA-MUTATED, HR+ ADVANCED BREAST CANCER. Read More »
